Home › RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program
 

Keywords :   


RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program

2013-01-31 09:52:58| Biotech - Topix.net

RXi Pharmaceuticals Corporation , a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that its second Phase 1 study with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and ... (more)

Tags: program trial phase completion

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Best No Bake Recipes Due by January 1
30.09The One-Room Schoolhouse
30.09Youth Tour: A Living Example of Cooperative Values
30.09Soaring Success
30.09Bunning enters supply agreement with Vermeer
30.09Santa Rosa County, Fla. Delays New Recycling Contract with WM
30.09Winters Bros. Scrap Plans for Waste Transfer Station in Yaphank, NY
30.09Aston Martin shares shaken after profit warning
More »